Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424296 | 0.83 | ALDH1A1 (0.38) | ALDH1A1HPGDKMT2AMEN1POLB | |
| SCHEMBL19418521 | 0.78 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL13134597 | 0.78 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL13253091 | 0.78 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL2816174 | 0.78 | RAB9A (0.38) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL2816178 | 0.78 | RAB9A (0.38) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL11013196 | 0.75 | ALDH1A1 (0.45) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL383266 | 0.74 | RAB9A (0.36) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL2815112 | 0.73 | RAB9A (0.35) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL2812042 | 0.72 | RAB9A (0.38) | ALDH1A1NPC1RAB9AHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2408306-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108140-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | ALDH1A1 2902/4885NPC1 731/4885RAB9A 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.